Michelle Maree McDonald

List of Publications by Year
in descending order

59 papers	4,439 citations	147566 31 h-index	143772 57 g-index
60 all docs	60 docs citations	60 times ranked	5956 citing authors

#	Article	IF	Citations
1	Bone remodeling during fracture repair: The cellular picture. Seminars in Cell and Developmental Biology, 2008, 19, 459-466.	2.3	705
2	Bone metastasis: the importance of the neighbourhood. Nature Reviews Cancer, 2016, 16, 373-386.	12.8	369
3	Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature Communications, 2015, 6, 8983.	5.8	296
4	The incorporation of strontium and zinc into a calciumâ€“silicon ceramic for bone tissue engineering. Biomaterials, 2010, 31, 3175-3184.	5.7	261
5	Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell, 2021, 184, 1330-1347.e13.	13.5	203
6	Novel Role of Y1 Receptors in the Coordinated Regulation of Bone and Energy Homeostasis. Journal of Biological Chemistry, 2007, 282, 19092-19102.	1.6	181
7	Optimal Timing of a Single Dose of Zoledronic Acid to Increase Strength in Rat Fracture Repair. Journal of Bone and Mineral Research, 2007, 22, 867-876.	3.1	171
8	Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood, 2017, 129, 3452-3464.	0.6	153
9	Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone, 2008, 43, 653-662.	1.4	143
10	Neuropeptide Y Knockout Mice Reveal a Central Role of NPY in the Coordination of Bone Mass to Body Weight. PLoS ONE, 2009, 4, e8415.	1.1	143
11	Manipulation of the Anabolic and Catabolic Responses With OP-1 and Zoledronic Acid in a Rat Critical Defect Model. Journal of Bone and Mineral Research, 2005, 20, 2044-2052.	3.1	125
12	The skeletal cellâ€derived molecule sclerostin drives bone marrow adipogenesis. Journal of Cellular Physiology, 2018, 233, 1156-1167.	2.0	116
13	Hypothalamic Regulation of Cortical Bone Mass: Opposing Activity of Y2 Receptor and Leptin Pathways. Journal of Bone and Mineral Research, 2006, 21, 1600-1607.	3.1	106
14	A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 2019, 134, 30-43.	0.6	99
15	Mechanical Load Increases in Bone Formation via a Sclerostin-Independent Pathway. Journal of Bone and Mineral Research, 2014, 29, 2456-2467.	3.1	91
16	The Murine Stanniocalcin 2 Gene Is a Negative Regulator of Postnatal Growth. Endocrinology, 2008, 149, 2403-2410.	1.4	82
17	Augmentation of autologous bone graft by a combination of bone morphogenic protein and bisphosphonate increased both callus volume and strength. Monthly Notices of the Royal Astronomical Society: Letters, 2013, 84, 106-111.	1.2	69
18	Intermittent PTH(1â€“34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures. Bone, 2010, 46, 852-859.	1.4	67

#	Article	IF	Citations
19	Zoledronic acid improves femoral head sphericity in a rat model of perthes disease. Journal of Orthopaedic Research, 2005, 23, 862-868.	1.2	66
20	Modeling bone morphogenetic protein and bisphosphonate combination therapy in wildâ€type and Nf1 haploinsufficient mice. Journal of Orthopaedic Research, 2008, 26, 65-74.	1.2	58
21	Prostate cancer cellâ€intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 2020, 21, e50162.	2.0	58
22	Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease. Nature Communications, 2021, 12, 2444.	5.8	58
23	Models of tibial fracture healing in normal and Nf1â€deficient mice. Journal of Orthopaedic Research, 2008, 26, 1053-1060.	1.2	56
24	Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. Journal of Orthopaedic Research, 2012, 30, 1541-1548.	1.2	53
25	Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype. Cancer Research, 2021, 81, 634-647.	0.4	50
26	Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcified Tissue International, 2017, 100, 433-448.	1.5	45
27	New Insights Into Osteoclast Biology. JBMR Plus, 2021, 5, e10539.	1.3	45
28	The use of heparan sulfate to augment fracture repair in a rat fracture model. Journal of Orthopaedic Research, 2006, 24, 636-644.	1.2	38
29	Î±-Actinin-3 deficiency is associated with reduced bone mass in human and mouse. Bone, 2011, 49, 790-798.	1.4	37
30	Endochondral fracture healing with external fixation in the Sost knockout mouse results in earlier fibrocartilage callus removal and increased bone volume fraction and strength. Bone, 2015, 71, 155-163.	1.4	31
31	Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities. JBMR Plus, 2019, 3, e10125.	1.3	29
32	Neuropeptide Y modulates fracture healing through Y₁ receptor signaling. Journal of Orthopaedic Research, 2013, 31, 1570-1578.	1.2	28
33	Cancer Cell Dormancy in Metastasis. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037556.	2.9	27
34	Loss of the Vitamin D Receptor in Human Breast Cancer Cells Promotes Epithelial to Mesenchymal Cell Transition and Skeletal Colonization. Journal of Bone and Mineral Research, 2019, 34, 1721-1732.	3.1	26
35	Matrix Metalloproteinaseâ€“Driven Endochondral Fracture Union Proceeds Independently of Osteoclast Activity. Journal of Bone and Mineral Research, 2013, 28, 1550-1560.	3.1	25
36	Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading. Journal of Bone and Mineral Research, 2018, 33, 486-498.	3.1	25

#	Article	IF	Citations
37	Signaling Between Tumor Cells and the Host Bone Marrow Microenvironment. Calcified Tissue International, 2014, 94, 125-139.	1.5	22
38	Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib). Bone, 2014, 59, 151-161.	1.4	22
39	Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation. Frontiers in Endocrinology, 2020, 11, 250.	1.5	22
40	Rapid cell culture and pre-clinical screening of a transforming growth factor-Î² (TGF-Î²) inhibitor for orthopaedics. BMC Musculoskeletal Disorders, 2010, 11, 105.	0.8	20
41	Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease. Current Osteoporosis Reports, 2017, 15, 532-541.	1.5	20
42	Characterization of the bone phenotype and fracture repair in osteopetrotic Incisors absent rats. Journal of Orthopaedic Research, 2011, 29, 726-733.	1.2	17
43	Bisphosphonate treatment and fracture repair. BoneKEy Osteovision, 2007, 4, 236-251.	0.6	17
44	Bisphosphonateâ€laden acrylic bone cement: Mechanical properties, elution performance, and in vivo activity. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2008, 87B, 482-491.	1.6	16
45	Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation. Calcified Tissue International, 2018, 102, 105-116.	1.5	15
46	Sclerostin Antibody Increases Callus Size and Strength but does not Improve Fracture Union in a Challenged Open Rat Fracture Model. Calcified Tissue International, 2017, 101, 217-228.	1.5	14
47	Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden. Blood, 2015, 126, 119-119.	0.6	14
48	Sclerostin antibody enhances bone formation in a rat model of distraction osteogenesis. Journal of Orthopaedic Research, 2018, 36, 1106-1113.	1.2	11
49	Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget, 2017, 8, 68047-68058.	0.8	10
50	Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume. Calcified Tissue International, 2018, 103, 298-310.	1.5	7
51	Increased anabolic bone response in Dkk1 KO mice following tibial compressive loading. Bone, 2020, 131, 115054.	1.4	7
52	Pretreatment with Pamidronate Decreases Bone Formation but Increases Callus Bone Volume in a Rat Closed Fracture Model. Calcified Tissue International, 2020, 106, 172-179.	1.5	5
53	Polyostotic hyperostosis in a domestic shorthair cat. Journal of Feline Medicine and Surgery, 2014, 16, 432-440.	0.6	3
54	Tumor Cell Dormancyâ€"a Hallmark of Metastatic Growth and Disease Recurrence in Bone. Current Molecular Biology Reports, 2018, 4, 50-58.	0.8	3

#	Article	IF	Citations
55	Visualisation of tumour cells in bone in vivo at single-cell resolution. Bone, 2022, 158, 116113.	1.4	2
56	Multiple Myeloma Progression: Dependence on Bone Marrow Adipose Tissue. Blood, 2016, 128, 3262-3262.	0.6	2
57	Augmented feedback in autistic disorder. South African Journal of Childhood Education, 2017, 7, 9.	0.2	0
58	Pre-clinical fracture repair investigations: Meeting report from the 30th Annual Meeting of the American Society for Bone and Mineral Research. IBMS BoneKEy, 2008, 5, 390-395.	0.1	0
59	Myeloma Bone Disease. , 2020, , 342-354.		0